| Sažetak | Unatoč opsežnim istraživanjima, još nisu pronađeni molekularni biljezi za
razlikovanje malignih od benignih neoplazmi štitnjače ili prepoznavanje podskupine
bolesnika s papilarnim karcinomom štitnjače (PKŠ) i višim rizikom za agresivnije
biološko ponašanje.
Prekomjerna ekspresija Piwil2 i HMGA2 proteina ili gena uočena je u različitim
malignim neoplazmama. Novije studije bile su usmjerene na razlikovanje benignih i
malignih neoplazmi štitnjače, ali korelacija s kliničkom uznapredovalosti PKŠ nije
istraživana.
Cilj je ovog istraživanja imunohistokemijska analiza ekspresije piwil2 i HMGA2
u papilarnim karcinomima s (PKSM) i bez metastaza (PKBM) u regionalnim limfnim
čvorovima te u folikularnim adenomima (FA), hiperplastičnim čvorovima i normalnom
tkivu štitnjače.
Retrospektivnom analizom 150 uzoraka (30 PKSM, 30 PKBM, 30 FA, 30
hiperplastičnih čvorova i 30 uzoraka normalnog tkiva štitnjače) utvrđena je povećana
ekspresija piwil2 i HMGA2 u PKŠ ( 96,7 %, 96,7 %) u odnosu na FA (73,3 %, 13,3 %),
hiperplastične čvorove (63,3 %, 3,3 %) i normalno tkivo štitnjače (76,7 %, 0 %),
P<0,001.
Nije bilo statistički značajne razlike u ekspresiji piwil2 i HMGA2 između skupina
PKSM i PKBM (100,0 % vs 96,7 %; 93,0 % vs 96,7 %). Veća ekspresija piwil2 i HMGA2
ne može se povezati s agresivnijim ponašanjem PKŠ-a.
Ekspresija HMGA2 s velikom osjetljivošću (97,78 %) i specifičnošću (100 %)
razlikuje papilarni karcinom od benignih promjena štitne žlijezde. |
| Sažetak (engleski) | Despite the extensive research, molecular markers for separating benign and
malignant neoplasms or identification of the subgroup of patients with papillary thyroid
carcinoma (PTC) and higher risk for more aggressive biological behaviour are yet to
be found.
The connection of Piwil2 and HMGA2 overexpression, either proteins or genes,
with more aggressive clinical course was identified in several malignant neoplasms.
Recent studies were focused on separating benign and malignant thyroid tumors. The
correlation between piwil2 and HMGA2 overexpression and clinical progression of PTC
has not been investgated.
The aim of this research was immunohistochemical analysis of piwil2 and
HMGA2 expression in PTC with and without regional lymph node metastasis (RLNM)
as well as in follicular adenomas (FA), hyperplastic nodules (HN) and non-neoplastic
thyroid tissue (NNTT).
By retrospective analysis of 150 tissue samples (30 PTC with RLNM and 30
PTC without RLNM, 30 FA, 30 HN, 30 NNTT) it was determined that expression of
piwil2 i HMGA2 was significantly higher in PTC (96,7%, 96,7%) as opposed to FA
(73,3%, 13,3%), HN (63,3%, 3,3%) and NNTT (76,7%, 0%), respecively, (P<0,001).
There was no statistically significant difference in expression of piwil2 and
HMGA2 between PTC with RLNM and PTC without RLNM (100,0% vs 96,7%; 93,0%
vs 96,7%, respectively). Overexpression of piwil2 and HMGA2 can not be associated
with more aggressive biological behaviour of PTC.
HMGA2 overexpression predicts PTC with high sensitiyity (97,78%) and
specificity (100%). |
